Bafna Pharmaceuticals, a BSE-listed company, declared that its has got nod from medicines and healthcare products regulatory agency of the UK (UK MHRA) for making a muscle relaxant drug 'Clonazepam' in the capacity of 0.5 mg and 2 mg.

In a declaration, Mr. Mahaveer Chand Bafna, Company Chairman and MD stated, ''The approval from UK MHRA will provide further momentum to our already expanding business in the European market... Following the recent launch of our research and development-formulation (FR and D) facility in Chennai, we will be filing dossiers for the ever growing UK and the European Markets.''

Clonazepam tablet is the ninth formulation sanction received from the UK MHRA by the Chennai-based company for contract manufacturing.

Clonazepam is prescribed for treating epilepsy, anxiety problems, panic disorder, initial treatment of mania or acute psychosis, hyperekplexia, many forms of parasomnia, restless legs syndrome, bruxism and rapid eye movement behaviour disorder.

Bafna has more than 76 products registered in Sri Lanka, Ukraine, Lao and Ghana. (With Inputs from Agencies)